Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 14, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	544	103	26	23	46	90
Market Cap Growth	-38.51%	299.81%	12.20%	-49.82%	-49.09%	384.92%
Enterprise Value	480	17	-1	-15	19	87
Last Close Price	7.84	1.58	1.28	1.37	3.15	13.50
PS Ratio	-	-	-	-	-	9.03
PB Ratio	7.53	1.35	1.22	0.69	0.84	3.47
P/TBV Ratio	7.89	1.36	1.22	0.69	0.84	3.49
EV/Sales Ratio	-	-	-	-	-	8.67
Debt / Equity Ratio	0.02	0.01	0.15	0.21	0.14	0.20
Asset Turnover	-	-	-	-	-	0.25
Inventory Turnover	11.15	10.88	7.03	6.12	5.63	4.24
Quick Ratio	14.87	10.11	2.79	3.36	11.55	2.73
Current Ratio	16.31	10.98	3.31	3.78	12.48	3.17
Return on Equity (ROE)	-53.82%	-95.00%	-110.27%	-64.19%	-68.67%	-68.33%
Return on Assets (ROA)	-34.23%	-54.42%	-50.20%	-30.65%	-32.78%	-22.20%
Return on Capital (ROIC)	-35.91%	-61.47%	-60.28%	-34.32%	-37.07%	-26.45%
Earnings Yield	-8.73%	-44.80%	-116.04%	-122.76%	-60.48%	-17.42%
FCF Yield	-8.02%	-40.60%	-105.78%	-112.20%	-53.02%	-13.88%
Buyback Yield / Dilution	-199.52%	-197.18%	-24.25%	-78.07%	-145.01%	-102.65%

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q